Novo Nordisk to present new data from key diabetes and obesity trials at the 60th annual meeting of the European Association for the Study of Diabetes

Bagsværd, Denmark, 6 September 2024 – Novo Nordisk today announced the presentation of 21 abstracts (7 oral and 14 short oral presentations) at the upcoming 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place from 9 to 13 September 2024 in Madrid, Spain.

In addition to the abstracts, data will also be presented in dedicated scientific symposia. These include results from the COMBINE clinical programme with IcoSema, a combination of once-weekly basal insulin icodec and once-weekly semaglutide, in people with type 2 diabetes, the FLOW trial evaluating semaglutide 1.0 mg on kidney outcomes in people with type 2 diabetes and chronic kidney disease, and amylin treatment for metabolic disease.

“Cardiometabolic conditions like diabetes, obesity, cardiovascular and kidney disease, all result from closely interlinked underlying risk factors and are among the most significant health challenges society faces today. Tailored treatment options that aim to holistically address these conditions are therefore needed,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “At EASD this year, we are showcasing new data from across our diabetes, obesity, cardiovascular and renal pipeline and portfolio, where we continue to push boundaries with the goal of advancing treatments in order to help more patients.”

Summary of presentations
Accepted data at the 60^th annual meeting of the EASD include the following oral and short oral presentations. Accepted abstracts include preliminary data that may be subject to change in final published manuscripts. Dates and times of the presentations and the abstracts can be found on the EASD website.

EASD scientific symposia

• Amylin for treatment of metabolic diseases (10 September 2024; 17.15-18.15 CEST)
• FLOW: the first dedicated kidney outcomes trial with a GLP-1 RA, semaglutide, in patients with T2D and CKD (11 September 2024; 09.00-10.30 CEST)
• Taking a COMBINEd approach: insulin icodec and semaglutide (11 September 2024; 17.30-18.30 CEST)
  
  

EASD oral and short oral presentations

Diabetes
Awiqli^® (once-weekly basal insulin icodec)

• Impact of age on the efficacy and safety of once-weekly insulin icodec versus once-daily insulin in type 2 diabetes (ONWARDS 1-5)
• Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline sodium-glucose cotransporter-2 inhibitor use: ONWARDS 1-5
• Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1-5
• Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5
• Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5
• No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes: ONWARDS 1-5
• No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec versus once-daily basal insulin in type 1 diabetes: ONWARDS 6
• Associations between mean fasting glucose levels and adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive type 2 diabetes: post hoc analysis of ONWARDS 5

Ozempic^® (once-weekly semaglutide 1.0 mg)

• Kidney, cardiovascular and all-cause mortality outcomes of semaglutide with or without baseline MRA use in type 2 diabetes and CKD: a FLOW trial analysis
  
  

Non-product

• Clinical implications of intentional weight loss in people living with T2D: A CPRD Aurum database study
  
  

Obesity
Wegovy^® (once-weekly semaglutide 2.4 mg)

• Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A pre-specified analysis from the SELECT trial
  
  

Saxenda^® (once-daily liraglutide 3.0 mg)

• Liraglutide 3.0 mg for the treatment of obesity in children aged 6 to <12 years: results from the first randomised, phase 3 study
  
  

Oral amycretin

• Safety, tolerability and weight reduction findings of oral amycretin: A novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
  
  

CagriSema

• CagriSema improves insulin sensitivity in diet-induced obese rats
• CagriSema-driven weight loss in diet-induced obese rats depends on counter-regulation of weight loss associated reduction in energy expenditure
• No clinically relevant QTc prolongation with cagrilintide: a thorough QT study in healthy participants
• Brain circuitry activated by cagrilintide, semaglutide and CagriSema in mice

Digital Health

• Multinational analysis of factors associated with missed bolus insulin injections using smart pen data
• Improvement in time in range after smart insulin pen initiation in Austria
• Regular at-home monitoring of stimulated dried blood spot C-peptide levels can detect changes in beta cell function early in individuals with recently diagnosed type 1 diabetes
• Continuous glucose monitoring in first-degree relatives with stage 2 diabetes

About Awiqli^® (once-weekly basal insulin icodec)
Awiqli^® (once-weekly insulin icodec) is a novel once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. In the EU, Awiqli^® is indicated for the treatment of diabetes mellitus in adults.

About Ozempic^® (semaglutide 1.0 mg)
In the EU, Ozempic^® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.

About Wegovy^® (semaglutide 2.4 mg)
In the EU, Wegovy^® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m² or greater (obesity), or adults with a BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy^® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg.

About Saxenda^® (liraglutide 3.0 mg)
In Europe, Saxenda^® is indicated along with diet and increased physical activity for weight management in adults with a BMI of 30 kg/m² or greater (obesity), or adults with a BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition. Saxenda^® is also indicated for adolescents from 12 years of age with obesity (BMI of 30 kg/m² or more) who weigh more than 60 kg.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com

Attachment

• PR240906-EASD 2024 data curtain raiser